Loading data for CTOR — first visit, this takes a few seconds.

Alerta

Citius Oncology Inc. (CTOR)

NasdaqCM: CTOR · Precio en tiempo real · USD

0.74

-0.18 (-19.57%)

Al cierre: Aug 18, 2026, 8:00 PM

-19.57% (1D)

No hay datos disponibles

Precio de compra	0.54
Capitalización de mercado	74.35M
Ingresos (TTM)	5.61M
Beneficio neto (TTM)	-42.51M
Beta	3.49
EPS (TTM)	-0.44
Ratio PER (TTM)	n/a
Adelante PE	n/a
P/B (TTM)	1.85
P/S (TTM)	13.25
Earnings Date	n/a

Precio de venta	0.98
Volumen	274,784
Volumen medio (20D)	80,365
Abierto	0.77
Anterior Cerrar	0.92
Rango del día	0.70 - 0.78
Rango de 52 semanas	0.49 - 2.25
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de CTOR

Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc....

[Leer más]

Industria Drug Manufacturers - Specialty & Generic

Sector Healthcare

IPO Fecha Dec 8, 2022

Empleados n/a

Bolsa de Valores NasdaqCM

Símbolo bursátil CTOR

Sitio web https://citiusonc.com/overview/default.aspx

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Citius Oncology fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -24.76M, un aumento de 17.08%.

Estados financieros

Sorpresa de resultados

Citius Oncology ha publicado sus resultados trimestrales en Aug 14, 2026:

Ingresos de $1.67M falla las estimaciones por $0, con Infinity% Crecimiento interanual.

EPS de -0.08 falla las estimaciones por -0.01, con 0.00% Crecimiento interanual.

Noticias

1 día hace · InvestorsHub

Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum

Citius Oncology Inc. (NASDAQ:CTOR) shares fell 10.

2 meses hace · Insider Monkey

Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts?

With an upside potential of 843.40%, Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is among the 7 Best Rated Penny Stocks to Buy According to Wall Street Analysts. On May 18, H.C. Wainwright analyst Sway...

3 meses hace · Pharmaceutical Technology

Citius raises $36.5m for Lymphir commercialisation

The capital includes a $25m term loan and a warrant exercise agreement expected to yield $11.5m.

4 meses hace · Simply Wall St.

Breakeven On The Horizon For Citius Oncology, Inc. (NASDAQ:CTOR)

Citius Oncology, Inc. ( NASDAQ:CTOR ) is possibly approaching a major achievement in its business, so we would like to...

5 meses hace · Insider Monkey

Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR

Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is one of the stocks that should double in 3 years. On February 13, Citius Pharmaceuticals officially transitioned into a revenue-generating company following...

Página 1 de 2

Citius Oncology Inc. (CTOR)